GlassScriptPhysician profile
Whitney Tobin
NPI 1548740616
$1,933.29
in general payments reported to CMS, 2019-2025
25 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $250 · 2023: $689 · 2024: $536 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.03 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.05 | 2022-2025 | |
| Gilead Sciences, INC. | $214.09 | 2024 | Trodelvy |
| Novo Nordisk INC | $208.40 | 2021-2023 | Rybelsus, Ozempic, Tresiba |
| Glaxosmithkline, LLC. | $184.10 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $127.44 | 2024 | Libtayo |
| Pfizer INC. | $101.84 | 2021-2024 | |
| Incyte Corporation | $95.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $83.38 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $80.99 | 2021 | |
| Lilly USA, LLC | $66.73 | 2021-2023 | Mounjaro |
| Astellas Pharma US INC | $51.85 | 2023-2024 | Veozah |
| Grifols USA, LLC | $43.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.67 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $37.29 | 2021-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.29 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.32 | 2021 | |
| Abbott Laboratories | $24.15 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $24.05 | 2023 | Repatha, Otezla |
| Dexcom, INC. | $22.01 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $19.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.17 | 2022 | |
| Almatica Pharma LLC | $16.14 | 2022 | |
| Mylan Specialty L.P. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.